In order to meet the biopharmaceutical industry’s need to characterize larger numbers of new chemical entities (NCEs) in various in vitro ADME assays, Charles River has implemented HT-ADME screening capabilities with a high-throughput workflow using lab automation, MRM method development, and data analysis tools to assist in making decisions on how to progress promising compounds.

Watch this webinar to learn how these in vitro data are used for many purposes during the drug discovery and development stage to triage and prioritize NCEs to enable in vivo PK, PK/PD, efficacy and TK studies.


  • Adrian Sheldon, PhD, AB, Director, In Vitro ADME, Charles River